Patients with human growth factor receptor 2–positive early breast cancer [HER2-positive (HER2+) EBC] who achieve pathologic complete response (pCR) after neoadjuvant therapy (NAT) have a lower recurrence rate than those without pCR (1–3). Here, ERBB2 is linked to breast cancer.